$510,000.00 in Sales Expected for Aadi Bioscience, Inc. (NASDAQ:AADI) This Quarter

Brokerages expect that Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating) will report sales of $510,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Aadi Bioscience’s earnings, with the highest sales estimate coming in at $780,000.00 and the lowest estimate coming in at $250,000.00. The firm is expected to announce its next quarterly earnings report before the market opens on Monday, January 1st.

On average, analysts expect that Aadi Bioscience will report full-year sales of $4.28 million for the current year, with estimates ranging from $2.25 million to $7.79 million. For the next fiscal year, analysts expect that the company will report sales of $5.84 million, with estimates ranging from $4.90 million to $6.78 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Aadi Bioscience.

Aadi Bioscience (NASDAQ:AADIGet Rating) last issued its earnings results on Thursday, March 17th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.05.

Several research analysts have recently weighed in on AADI shares. HC Wainwright reduced their price target on shares of Aadi Bioscience from $49.00 to $48.00 and set a “buy” rating for the company in a report on Monday, April 11th. Jefferies Financial Group began coverage on shares of Aadi Bioscience in a research note on Tuesday, January 11th. They issued a “buy” rating and a $45.00 target price for the company. Finally, Zacks Investment Research downgraded Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, January 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $43.20.

In other Aadi Bioscience news, insider Neil Desai sold 3,550 shares of the business’s stock in a transaction that occurred on Friday, March 18th. The stock was sold at an average price of $20.07, for a total value of $71,248.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.10% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. bought a new stake in shares of Aadi Bioscience during the 3rd quarter worth approximately $1,322,000. RTW Investments LP bought a new stake in shares of Aadi Bioscience during the 3rd quarter worth approximately $21,336,000. Rock Springs Capital Management LP bought a new stake in shares of Aadi Bioscience during the 3rd quarter worth approximately $22,459,000. US Bancorp DE bought a new stake in shares of Aadi Bioscience during the 3rd quarter worth approximately $98,000. Finally, BlackRock Inc. bought a new stake in shares of Aadi Bioscience during the 3rd quarter worth approximately $478,000. Institutional investors own 55.36% of the company’s stock.

NASDAQ AADI opened at $14.60 on Friday. The stock has a market cap of $305.58 million, a price-to-earnings ratio of -1.16 and a beta of 1.58. The business has a 50 day simple moving average of $17.21 and a 200 day simple moving average of $20.95. Aadi Bioscience has a 52-week low of $14.31 and a 52-week high of $49.80.

About Aadi Bioscience (Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Featured Articles

Get a free copy of the Zacks research report on Aadi Bioscience (AADI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.